{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:29:40Z","timestamp":1790094580500,"version":"4.0.1"},"reference-count":61,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2026,9]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Biologic therapies have revolutionized psoriasis management, yet inter\u2010individual response varies significantly and reliable predictors of complete skin clearance remain unclear.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n This study aimed to identify prognostic predictors of biologic efficacy in patients with psoriasis through a systematic review and meta\u2010analysis.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We systematically searched four databases (from their inception to January 28, 2026). Studies were screened and data extracted per predefined criteria; quality was assessed using the Newcastle\u2010Ottawa Scale (NOS), and analyses were performed in Stata 15.0.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Thirty studies (\n n<\/jats:italic>\n \u2009=\u200913,902) were included. Negative predictors of clearance included older age (odds ratio [OR] 0.99, 95% CI 0.98\u20130.99,\n p<\/jats:italic>\n \u2009<\u20090.001), higher body mass index (OR 0.94, 95% CI 0.92\u20130.97,\n p<\/jats:italic>\n \u2009<\u20090.001), comorbidities (OR 0.75, 95% CI 0.63\u20130.9,\n p<\/jats:italic>\n \u2009=\u20090.002), and involvement of special areas (OR 0.71, 95% CI 0.56\u20130.89,\n p<\/jats:italic>\n \u2009=\u20090.003). Conversely, a positive family history (OR 1.42, 95% CI 1.18\u20131.71,\n p<\/jats:italic>\n \u2009<\u20090.001) emerged as a significant predictor associated with better outcomes. No significant associations were observed for other analysed variables.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Older age, higher comorbidity burden, obesity, and special\u2010site involvement are associated with poorer biologic response in psoriasis, whereas family history is associated with better outcomes. These readily available baseline factors facilitate phenotype\u2010based risk stratification and may guide treatment selection in clinical practice.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/jdv.70462","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T12:52:42Z","timestamp":1776430362000},"page":"1469-1480","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Predictors of clinical response to biologics in psoriasis: A systematic review and meta\u2010analysis"],"prefix":"10.1111","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7938-4572","authenticated-orcid":false,"given":"Xuerui","family":"Mao","sequence":"first","affiliation":[{"name":"Department of Dermatology The Affiliated Wuxi People's Hospital of Nanjing Medical University Jiangsu Wuxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0109-8452","authenticated-orcid":false,"given":"Shuo","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Affiliated Wuxi People's Hospital of Nanjing Medical University Jiangsu Wuxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panyu","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Affiliated Wuxi People's Hospital of Nanjing Medical University Jiangsu Wuxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5749-2857","authenticated-orcid":false,"given":"Lei","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Dermatology Jiangnan University Medical Center Jiangsu Wuxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2172-4406","authenticated-orcid":false,"given":"Lei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Affiliated Wuxi People's Hospital of Nanjing Medical University Jiangsu Wuxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths CEM","year":"2021","journal-title":"Lancet"},{"key":"e_1_2_13_3_1","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1080\/14712598.2025.2584387","article-title":"Real\u2010world effectiveness and predictors of complete skin clearance (PASI 100) with anti\u2010IL\u201023 monoclonal antibodies in moderate\u2010to\u2010severe psoriasis: a retrospective cohort study","volume":"25","author":"Michelucci A","year":"2025","journal-title":"Expert Opin Biol Ther"},{"key":"e_1_2_13_4_1","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta\u2010analysis","volume":"5","author":"Sbidian E","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_13_5_1","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris \u2010 part 1: treatment and monitoring recommendations","volume":"34","author":"Nast A","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_13_6_1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40291-017-0261-4","article-title":"HLA\u2010C*06:02 does not predispose to clinical response following long\u2010term Adalimumab treatment in psoriatic patients: a retrospective cohort study","volume":"21","author":"Talamonti M","year":"2017","journal-title":"Mol Diagn Ther"},{"key":"e_1_2_13_7_1","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/jdv.19682","article-title":"Drug survival, effectiveness and safety of ixekizumab for moderate\u2010to\u2010severe psoriasis up to 5\u2009years","volume":"38","author":"Mastorino L","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_13_8_1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40257-023-00816-1","article-title":"Guselkumab\u2010treated patients with plaque psoriasis who achieved complete skin clearance for \u2265\u2009156 consecutive weeks: a post\u2010hoc analysis from the VOYAGE 1 clinical trial","volume":"25","author":"Puig L","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"e_1_2_13_9_1","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1684\/ejd.2020.3878","article-title":"Real\u2010world data on the use of secukinumab as treatment for moderate\u2010to\u2010severe psoriasis in Chinese patients","volume":"30","author":"Huang H","year":"2020","journal-title":"Eur J Dermatol"},{"key":"e_1_2_13_10_1","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1080\/09546634.2020.1839009","article-title":"Clinical efficacy and safety of secukinumab for psoriasis in a real\u2010world setting in Turkey","volume":"33","author":"Y\u0131ld\u0131r\u0131m FE","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"e_1_2_13_11_1","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1080\/14712598.2021.1948530","article-title":"Predictive factors of lack of response to adalimumab among bio\u2010naive patients suffering from moderate\u2010to severe psoriasis: analysis of a multicenter data collection in Italy","volume":"21","author":"Zangrilli A","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"e_1_2_13_12_1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/bjd.15387","article-title":"Role of the HLA\u2010C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients","volume":"177","author":"Talamonti M","year":"2017","journal-title":"Br J Dermatol"},{"key":"e_1_2_13_13_1","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15231","article-title":"Effectiveness and safety of guselkumab for the treatment of psoriasis in real\u2010world settings at 24\u2009weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group","volume":"35","author":"Del Alc\u00e1zar E","year":"2022","journal-title":"Dermatol Ther"},{"key":"e_1_2_13_14_1","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.3390\/ijms24076111","article-title":"Blood cell biomarkers of inflammation and cytokine levels as predictors of response to biologics in patients with psoriasis","volume":"24","author":"Andersen CSB","year":"2023","journal-title":"Int J Mol Sci"},{"key":"e_1_2_13_15_1","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.3390\/jcm13143992","article-title":"Blood\u2010count\u2010derived inflammatory markers as predictors of response to biologics and small\u2010molecule inhibitors in psoriasis: a multicenter study","volume":"13","author":"Morariu SH","year":"2024","journal-title":"J Clin Med"},{"key":"e_1_2_13_16_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10787-018-0530-9","article-title":"IL\u20101\u03b2, IL\u201017A and combined phototherapy predicts higher while previous systemic biologic treatment predicts lower treatment response to etanercept in psoriasis patients","volume":"27","author":"Liu Y","year":"2019","journal-title":"Inflammopharmacology"},{"key":"e_1_2_13_17_1","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s13555-025-01394-2","article-title":"Predictive factors for super responder status and long\u2010term effectiveness of Guselkumab in psoriasis: a multicenter retrospective study","volume":"15","author":"Mortato E","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"e_1_2_13_18_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1146\/annurev-publhealth-051920-114020","article-title":"Methods to address confounding and other biases in meta\u2010analyses: review and recommendations","volume":"43","author":"Mathur MB","year":"2022","journal-title":"Annu Rev Public Health"},{"key":"e_1_2_13_19_1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12967-023-04847-4","article-title":"A novel online calculator based on clinical features and hematological parameters to predict total skin clearance in patients with moderate to severe psoriasis","volume":"22","author":"Jiang Y","year":"2024","journal-title":"J Transl Med"},{"key":"e_1_2_13_20_1","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/1346-8138.13681","article-title":"Clinical factors predicting the therapeutic response to ustekinumab in patients with moderate to severe chronic plaque psoriasis","volume":"44","author":"Hwang YJ","year":"2017","journal-title":"J Dermatol"},{"key":"e_1_2_13_21_1","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/1346-8138.15670","article-title":"Clinical outcomes in adult patients with plaque psoriasis treated with ustekinumab under real\u2010world practice in Korea: a prospective, observational, multi\u2010center, postmarketing surveillance study","volume":"48","author":"Youn SW","year":"2021","journal-title":"J Dermatol"},{"key":"e_1_2_13_22_1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000492784","article-title":"Depression symptoms predict worse clinical response to Etanercept treatment in psoriasis patients","volume":"235","author":"Jin W","year":"2019","journal-title":"Dermatology"},{"key":"e_1_2_13_23_1","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/bjd.13056","article-title":"Human leucocyte antigen\u2010Cw6 as a predictor for clinical response to ustekinumab, an interleukin\u201012\/23 blocker, in Chinese patients with psoriasis: a retrospective analysis","volume":"171","author":"Chiu HY","year":"2014","journal-title":"Br J Dermatol"},{"key":"e_1_2_13_24_1","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.1111\/jocd.15217","article-title":"Ixekizumab treatment in patients with moderate\u2010to\u2010severe plaque psoriasis in a real\u2010world clinical setting","volume":"21","author":"Demirel \u00d6\u011f\u00fct N","year":"2022","journal-title":"J Cosmet Dermatol"},{"key":"e_1_2_13_25_1","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2024.2321188","article-title":"Short\u2010term effectiveness and potential factors of ustekinumab based on real\u2010world data in Chinese psoriasis patients","volume":"35","author":"Li X","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"e_1_2_13_26_1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s40257-025-00918-y","article-title":"The impact of family history on clinical presentation and biologic treatment response in patients with psoriasis: a multicenter prospective cohort study","volume":"26","author":"Jiang Y","year":"2025","journal-title":"Am J Clin Dermatol"},{"key":"e_1_2_13_27_1","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.jaci.2018.11.038","article-title":"HLA\u2010C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis","volume":"143","author":"Dand N","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_2_13_28_1","doi-asserted-by":"crossref","first-page":"adv00579","DOI":"10.2340\/actadv.v101.351","article-title":"Predictors of response to biologics in patients with moderate\u2010to\u2010severe psoriasis: a Danish Nationwide cohort study","volume":"101","author":"Schwarz CW","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_13_29_1","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/jdv.15077","article-title":"Psoriasis area and severity index response in moderate\u2010severe psoriatic patients switched to adalimumab: results from the OPPSA study","volume":"32","author":"Talamonti M","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_13_30_1","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/jdv.16202","article-title":"Real\u2010world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response","volume":"34","author":"Rompoti N","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_13_31_1","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14066","article-title":"The effectiveness and safety of ixekizumab in psoriasis patients under clinical practice conditions: a Spanish multicentre retrospective study","volume":"33","author":"Rivera R","year":"2020","journal-title":"Dermatol Ther"},{"key":"e_1_2_13_32_1","doi-asserted-by":"crossref","first-page":"6371","DOI":"10.3390\/jcm14186371","article-title":"Predictors of super\u2010responder status to anti\u2010IL\u201023 therapies in moderate\u2010to\u2010severe plaque psoriasis: a real\u2010world Monocenter study","volume":"14","author":"Di Giulio S","year":"2025","journal-title":"J Clin Med"},{"key":"e_1_2_13_33_1","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2147\/PTT.S533005","article-title":"Long\u2010term real\u2010world effectiveness and drug survival of Guselkumab in patients with psoriasis: a 5\u2010year retrospective study","volume":"15","author":"Mortato E","year":"2025","journal-title":"Psoriasis"},{"key":"e_1_2_13_34_1","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2026.2617770","article-title":"Risankizumab super responders in moderate\u2010to\u2010severe psoriasis: prevalence, predictors, and long\u2010term maintenance in a multicenter, international, real\u2010world cohort","volume":"37","author":"Orsini D","year":"2026","journal-title":"J Dermatolog Treat"},{"key":"e_1_2_13_35_1","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2025.2563657","article-title":"Predictive factors for early super response to bimekizumab in 341 patients with psoriasis\u2010a 24\u2010week short\u2010term multicenter real\u2010life experience","volume":"36","author":"\u00c7etinarslan T","year":"2025","journal-title":"J Dermatolog Treat"},{"key":"e_1_2_13_36_1","first-page":"712","article-title":"Clinical characterisation of super\u2010responders and super\u2010non\u2010responders in psoriasis patients treated with interleukin\u201017 inhibitors: a real\u2010world study","volume":"91","author":"Zhang L","year":"2025","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"e_1_2_13_37_1","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s13555-020-00436-1","article-title":"A real\u2010world evaluation of the long\u2010term safety and efficacy of infliximab in the treatment moderate\u2010to\u2010severe psoriasis","volume":"10","author":"Haque EK","year":"2020","journal-title":"Dermatol Ther"},{"key":"e_1_2_13_38_1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/bjd\/ljad446","article-title":"Characteristics of \u2018super responders\u2019 and \u2018super nonresponders\u2019 to first biologic monotherapy for psoriasis: a nested case\u2010control study","volume":"190","author":"Mason KJ","year":"2024","journal-title":"Br J Dermatol"},{"key":"e_1_2_13_39_1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41584-025-01326-6","article-title":"The obesity\u2010inflammation axis in psoriatic disease: mechanisms and therapeutic strategies","volume":"22","author":"Haberman RH","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"e_1_2_13_40_1","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/jid.2010.103","article-title":"Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co\u2010morbid conditions","volume":"130","author":"Davidovici BB","year":"2010","journal-title":"J Invest Dermatol"},{"key":"e_1_2_13_41_1","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2015.00001","article-title":"Management of moderate to severe psoriasis in patients with metabolic comorbidities","volume":"2","author":"Gisondi P","year":"2015","journal-title":"Front Med"},{"key":"e_1_2_13_42_1","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s40261-021-01080-z","article-title":"Impact of body mass index on the efficacy of biological therapies in patients with psoriasis: a real\u2010world study","volume":"41","author":"Pirro F","year":"2021","journal-title":"Clin Drug Investig"},{"key":"e_1_2_13_43_1","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/09546634.2019.1626973","article-title":"Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis","volume":"31","author":"Pinter A","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"e_1_2_13_44_1","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1468-3083.2012.04500.x","article-title":"Re\u2010evaluation of the risk for major adverse cardiovascular events in patients treated with anti\u2010IL\u201012\/23 biological agents for chronic plaque psoriasis: a meta\u2010analysis of randomized controlled trials","volume":"27","author":"Tzellos T","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_13_45_1","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.3390\/jcm13092552","article-title":"Real\u2010life effectiveness and safety of Guselkumab in patients with psoriasis who have an inadequate response to Ustekinumab: a 3\u2010year multicenter study","volume":"13","author":"Megna M","year":"2024","journal-title":"J Clin Med"},{"key":"e_1_2_13_46_1","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s13555-025-01416-z","article-title":"Optimizing Tildrakizumab dosing in psoriasis: a 52\u2010week multicenter retrospective study comparing 100 mg and 200 mg\u2010IL PSO (Italian landscape psoriasis)","volume":"15","author":"Valenti M","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"e_1_2_13_47_1","first-page":"1","article-title":"Impact of weight\u2010loss interventions on psoriasis severity: a systematic review and meta\u2010analysis","author":"Morrow S","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_13_48_1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00403-017-1741-4","article-title":"Dermatological comorbidity in psoriasis: results from a large\u2010scale cohort of employees","volume":"309","author":"Zander N","year":"2017","journal-title":"Arch Dermatol Res"},{"key":"e_1_2_13_49_1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age\u2010related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Mangoni AA","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_13_50_1","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/1346-8138.16856","article-title":"Effect of the age of onset on epidemiology, clinical features, and comorbidity of geriatric psoriasis","volume":"50","author":"Chen C","year":"2023","journal-title":"J Dermatol"},{"key":"e_1_2_13_51_1","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3569","article-title":"Disease and treatment characteristics in geriatric psoriasis: a patient survey comparing age groups","volume":"100","author":"Winden MEC","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_13_52_1","doi-asserted-by":"crossref","first-page":"e454","DOI":"10.1111\/jdv.17944","article-title":"Family history of psoriasis: a novel protective factor for therapy switch in patients treated with Secukinumab or Ixekizumab","volume":"36","author":"Manzo Margiotta F","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_13_53_1","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0190-9622(85)70188-0","article-title":"Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris","volume":"13","author":"Henseler T","year":"1985","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_13_54_1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1046\/j.1365-2133.2003.05115.x","article-title":"Psoriasis patients who are homozygous for the HLA\u2010Cw*0602 allele have a 2.5\u2010fold increased risk of developing psoriasis compared with Cw6 heterozygotes","volume":"148","author":"Gudjonsson JE","year":"2003","journal-title":"Br J Dermatol"},{"key":"e_1_2_13_55_1","first-page":"e1","article-title":"Adult genital psoriasis: An updated review for clinicians","volume":"65","author":"Wu M","year":"2024","journal-title":"Australas J Dermatol"},{"key":"e_1_2_13_56_1","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.2147\/CCID.S417679","article-title":"Nail psoriasis: An updated review of currently available systemic treatments","volume":"16","author":"Battista T","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"e_1_2_13_57_1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40273-014-0226-y","article-title":"Biological therapies for the treatment of severe psoriasis in patients with previous exposure to biological therapy: a cost\u2010effectiveness analysis","volume":"33","author":"Sawyer LM","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"e_1_2_13_58_1","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1111\/jdv.18474","article-title":"Super\u2010response to guselkumab treatment in patients with moderate\u2010to\u2010severe psoriasis: age, body weight, baseline psoriasis area and severity index, and baseline Investigator's global assessment scores predict complete skin clearance","volume":"36","author":"Reich K","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_13_59_1","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jid.2017.09.044","article-title":"Differential drug survival of second\u2010line biologic therapies in patients with psoriasis: observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"138","author":"Iskandar IYK","year":"2018","journal-title":"J Invest Dermatol"},{"key":"e_1_2_13_60_1","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/bjd.12670","article-title":"Psoriasis and smoking: a systematic review and meta\u2010analysis","volume":"170","author":"Armstrong AW","year":"2014","journal-title":"Br J Dermatol"},{"key":"e_1_2_13_61_1","doi-asserted-by":"crossref","DOI":"10.1177\/0300060520964024","article-title":"Impact of smoking on psoriasis risk and treatment efficacy: a meta\u2010analysis","volume":"48","author":"Zhou H","year":"2020","journal-title":"J Int Med Res"},{"key":"e_1_2_13_62_1","first-page":"e140","article-title":"Drug survival of biological therapies in smokers and non\u2010smokers with psoriasis: a retrospective cohort study using data from the Australasian Psoriasis Registry","volume":"66","author":"May F","year":"2025","journal-title":"Australas J Dermatol"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70462","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.70462","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70462","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:05:25Z","timestamp":1787670325000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.70462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":61,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1111\/jdv.70462"],"URL":"https:\/\/doi.org\/10.1111\/jdv.70462","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"2026-01-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}